Anti-Human placental lactogen (epitope 2) antibody [INN-hPL-37] (ab11396)


  • Product nameAnti-Human placental lactogen (epitope 2) antibody [INN-hPL-37]
  • Description
    Mouse monoclonal [INN-hPL-37] to Human placental lactogen (epitope 2)
  • SpecificityRadioimmunological direct binding studies were performed with 125I-labelled. hPL, hGH, hPRL and increasing amounts of INN-hPL-37. In addition, competitive RIA with unlabelled hGH, hPRL and hPL were used for characterization. In competitive RIA cross reactivity with hGH and hPRL was below 1%. Direct binding demonstrated 39% reactivity with hGH but no cross reactivity with hPRL.
  • Tested applicationsSuitable for: RIAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Human placental lactogen.

  • General notesThis product should be stored undiluted. Storage in frost free freezers is not recommended. Should this product contain a precipitate we recommend microcentrifugation before use.


  • FormLiquid
  • Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
  • Storage bufferPreservative: 0.09% Sodium Azide.
  • Concentration information loading...
  • PurityProtein A purified
  • Purification notesPurification by affinity chromatography.
  • ClonalityMonoclonal
  • Clone numberINN-hPL-37
  • Myelomax63-Ag8.653
  • IsotypeIgG1
  • Research areas


Our Abpromise guarantee covers the use of ab11396 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
RIA Use at an assay dependent dilution.


  • RelevancePlacental lactogen is a member of the somatotropin/prolactin family of hormones and plays an important role in growth control. The gene is located at the growth hormone locus on chromosome 17 along with four other related genes in the same transcriptional orientation; an arrangement which is thought to have evolved by a series of gene duplications. Although the five genes share a remarkably high degree of sequence identity, they are expressed selectively in different tissues. Alternative splicing generates additional isoforms of each of the five growth hormones, leading to further diversity and potential for specialization. This particular family member is expressed mainly in the placenta and utilizes multiple transcription initiation sites.
  • Cellular localizationSecreted
  • Database links
  • Alternative names
    • choriomammotropin antibody
    • Chorionic somatomammotropin A antibody
    • Chorionic somatomammotropin hormone 1 (placental lactogen) antibody
    • chorionic somatomammotropin hormone 1 antibody
    • Chorionic somatomammotropin hormone 2 antibody
    • CS 1 antibody
    • CS-2 antibody
    • CS-B antibody
    • CSA antibody
    • CSB antibody
    • CSH1 antibody
    • CSMT antibody
    • hCSB antibody
    • Lactogen precursor antibody
    • Lactogen, placental antibody
    • PL antibody
    • placental lactogen antibody
    see all

Anti-Human placental lactogen (epitope 2) antibody [INN-hPL-37] images

  • ab11396 at 1/100 staining human BeWo cells (placenta, choriocarcinoma) by ICC/IF. The cells were paraformaldehyde fixed and blocked with BSA prior to incubation with the antibody for 30 minutes. A FITC conjugated goat anti-mouse IgG antibody was used as the secondary antibody. The image is shown in the upper right hand panel. In this experiment ab15554 was used as a positive control (bottom left hand panel). Cells were counter stained with DAPI (upper left hand panel).

    See Abreview

References for Anti-Human placental lactogen (epitope 2) antibody [INN-hPL-37] (ab11396)

ab11396 has not yet been referenced specifically in any publications.

Product Wall

Abcam has not validated the combination of species/application used in this Abreview.
Application Western blot
Sample Human Recombinant protein (Human recombinant hPL)
Loading amount 0.1 µg
Specification Human recombinant hPL
Blocking step Milk as blocking agent for 17 hour(s) and 0 minute(s) · Concentration: 5%

Dr. Stoil Dmitrov

Verified customer

Submitted Apr 16 2007

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (BeWo, placenta, choriocarcinoma)
Specification BeWo, placenta, choriocarcinoma
Fixative Paraformaldehyde
Blocking step BSA as blocking agent for 30 minute(s) · Concentration: 1%

Dr. Stoil Dmitrov

Verified customer

Submitted Apr 11 2007